Skip to main content

Table 2 Weights assigned to outcomes included in the benefit-harm analyses of low dose aspirin for primary prevention of cardiovascular disease and colorectal cancer

From: Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer

Outcome 5-year survival Weight
Myocardial infarction [34] 79.2 % 0.5
Ischemic stroke [35] 42.0 % 1.0
Hemorrhagic stroke [35] 42.0 % 1.0
Gastrointestinal bleeds [36] 45.5 % (3-year) 1.0
Colorectal cancer [37] 65.2 % 0.5
Biliary cancer [37] 18.3 % 1.0
Esophageal cancer [37] 18.3 % 1.0
Gastric cancer [37] 30.3 % 1.0
Breast cancer [37] 89.6 % 0.5
Lung cancer [37] 18.0 % 1.0
Prostate cancer [37] 98.9 % 0.1
Hematological cancer [37] 48.5 –85.8 % 0.5
Pancreatic cancer [37] 7.9 % 1.0
Bladder cancer [37] 77.4 % 0.5
Gynecological cancer [37] 45.8 –81.6 % 0.5
Renal cancer [37] 73.6 % 0.5
  1. These weights can be adjusted individually on [http://www.benefit-harm-balance.com]